Monday, November 05, 2018 2:58:22 PM
One could look at success in the PISCES trial as an indicator of what's possible in other solid tumor cancers as well. This may also impact the company's valuation. There is such an enormous unmet need for advanced solid cancers. In the US, for example, I believe there are approximately 40k-50k new cases of TNBC diagnosed each year and only around 5% respond to anti-pd-1 therapy. Would Oncosec's current TNBC trial be factored in to the company's valuation given hypothetical success in the PISCES P2b trial? We already have a glimpse of what happens when anti-pd-1 treatments follow a single treatment cycle of ImmunoPulse IL-12 in TNBC - responses in both patients who went straight to anti-pd-1 treatment. There is mounting evidence now that the ImmunoPulse platform works across multiple solid cancers.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM